Expression of IL-13Rα2 in liver cancer cells and its effect on targeted therapy of liver cancer

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 6, 2010, Pages 839-846

  Hou, Lingling ^a   Du, Juan ^a   Wang, Jianwei ^b   Liu, Yanfeng ^a   Sun, Weimin ^a   Zheng, Yanpeng ^a   Zhang, Lishu ^a   Hu, Honggang ^a   Dai, Xinxian ^a   Guan, Weijun ^c   Ma, Yuehui ^c   Hong, Tao ^a  

^a BEIJING JIAOTONG UNIVERSITY   (China)

^b INSTITUTE OF PATHOGEN BIOLOGY   (China)

^c INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

IL 13R 2; Liver cancer; SIRNA; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 13 RECEPTOR ALPHA2; SMALL INTERFERING RNA; TUMOR MARKER;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; HUMAN; LIVER TUMOR; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; LIVER NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 77951643620     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-009-0724-z     Document Type: Article

References (21)

1. Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, O'Hara RM Jr, Beier DR, Turner KJ, Wood CR, Collins M (1998) The murine IL-13 receptor a2: molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J Immunol 161:2317-2324
2. Du J, Zheng YP, Sun W, Hu HG, Hou LL, Hong T (2008) Targeted killing effect of IL-13 diphtheria toxin fusion protein and DT389-hIL13-13E13K. J Med Res 37(10):31-36
3. Fluckiger AC, Brière F, Zurawski G, Bridon JM, Banchereau J (1994) IL-13 has only a subset of IL-4-like activities on B chronic lymphocytic leukaemia cells. Immunology 83(3):397-403
4. Forner A, Hessheimer AJ, Isabel Real M, Bruix J (2006) Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 60:89-98
5. Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanski M, Manns MP (2005) Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 92(10):1862-1868
6. Husain SR, Puri RK (2000) Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft. Blood 95(11):3506-3513
7. Jiang J, Nilsson-Ehle P, Xu N (2006) Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 5:4
8. Joshi BH, Plautz GE, Puri RK (2000) Interleukin-13 Receptor α Chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 60(5):1168-1172
9. Kawakami K, Kawakami M, Sony PJ, Husain SR, Puri RK (2001) In vivo overexpression of IL-13 receptor α2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 194(12):1743-1754
10. Kawakami M, Kawakami K, Kasperbauer JL, Hinkley LL, Tsukuda M, Strome SE, Puri RK (2003) Interleukin-13 receptor α2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res 9(17):6381-6388
11. Kawakami K, Kawakami M, Puri RK (2004a) SpeciWcally targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease. Mol Cancer Ther 3(2):137-147
12. Kawakami M, Kawakami K, Takahashi S, Abe M, Puri RK (2004b) Analysis of interleukin-13 receptor α2 expression in human pediatric brain tumors. Cancer 101(5):1036-1042
13. Kawakami K, Kioi M, Liu Q, Kawakami M, Puri RK (2005) Evidence that IL-13Rα2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy. J Immunother 28(3):193-202
14. Kioi M, Kawakami K, Puri RK (2004) Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and pseudomonas exotoxin. Clin Cancer Res 10:6231-6238
15. Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK (2006) Interleukin-13 receptor α2 China: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 107(6):1407-1418
16. Kioi M, Shimamura T, Nakashima H, Hirota M, Tohnai I, Husain SR, Puri RK (2009) IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. Int J Cancer 124(6):1440-1448
17. Kunwar S, Chang SM, Prados MD, Berger MS, Sampson JH, Croteau D, Sherman JW, Grahn AY, Shu VS, Dul JL, Husain SR, Joshi BH (2006) Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 20(4):E15
18. Li C, Hall WA, Jin N, Todhunter DA, Panoskaltsis-Mortari A, Vallera DA (2002) Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng 15(5):419-427
19. Parkin DM, Bray F, Ferlay J, Pisani P (2002) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-108
20. Shimamura T, Fujisawa T, Husain SR, Kioi M, Nakajima A, Puri RK (2008) Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. J Immunol 181:4656-4665
21. Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY, Sherman JW, Husain SR, Puri RK (2007) Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase I study of final safety results. Neurosurgery 61(5):1031-1038